JEFFREY RETTIG: Open Payments
NPI 1528005550 · GROESBECK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$669 in 31 payments from 16 companies in 2025. Trend: 2023 $704 · 2024 $844 · 2025 $669
Food & beverage: $669
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| Sumitomo Pharma America, Inc. | 1 | $71 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $66 |
| Lilly USA, LLC | 3 | $55 |
| PFIZER INC. | 2 | $50 |
| Lundbeck LLC | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $37 |
| GlaxoSmithKline, LLC. | 1 | $23 |
Products named: REXULTI, GEMTESA, Kerendia, FARXIGA, PREVNAR 20, Auvelity, JARDIANCE, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
